Clinical Pharmacokinetics of Carbamazepine

Blom S Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G 32883). Lancet 1962; 1: 839–40

Blom S Tic douloureux treated with new anti-convulsant. Arch Neurol 1963; 9: 285–90

Taylor JC Brauer S Espir MLE Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J 1981; 57: 16–8

Bertilsson L Tomson T Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11–epoxide. Clin Pharmacokinet 1986; 11: 177–98

Faigle JW Feldmann KF Carbamazepine biotransformation. In: Woodbury DM Penry JK Pippenger CE eds Antiepileptic drugs. 2nd edn New York: Raven Press 1982: 483 95

Morselli PL Bossi L Carbamazepine: absorption, distribution, and excretion. In: Woodbury DM Penry JK , Pippenger CE eds Antiepileptic drugs. 2nd edn New York: Raven Press 1982: 465 82

Höppener RJ Kuyer A Meijer JWA Hulsman J Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980; 21: 341–50

Tomson T Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch Neurol 1984; 41: 830–4

Neuvonen PJ Bioavailability and central side effects of different carbamazepine tablets. J Clin Pharmacol Ther Toxicol 1985; 23: 226–32

Wada JA Troupin AS Friel P Remick R Leal K Pearmain J Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine. Epilepsia 1978; 19: 251–5

Bertilsson L Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 1978; 3: 128–43

Levy RH Schmidt D Utility of free level monitoring of antiepileptic drugs. Epilepsia 1985; 26: 199–205

Eichelbaum M Bertilsson L Lund L Palmér L Sjöqvist F Plasma levels of carbamazepine and carbamazepine-10,11–epoxide during treatment of epilepsy. Eur J Clin Pharmacol 1976; 9: 417–21

Tomson T Tybring G Bertilsson L Ekbom K Rane A Carbamazepine therapy in trigeminal neuralgia. Clinical effects in relation to plasma concentration. Arch Neurol 1980; 37: 699–703

Tomson T Tybring G Bertilsson L Single dose kinetics and metabolism of carbamazepine-10,11–epoxide. Clin Pharmacol Ther 1983; 33: 58–65

Bertilsson L Höjer B Tybring G Osterloh J Rane A Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 1980; 27: 83–8

Eichelbaum M Tomson T Tybring G Bertilsson L Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet 1985; 10: 80–90

Bertilsson L Tomson T Tybring G Pharmacokinetics: time-dependent changes—autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986; 26: 459–62

Eichelbaum M Ekbom K Bertilsson L Ringberger VA Rane A Plasma kinetics of carbamazepine and its epoxidè metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975; 8: 337–41

Hockings N Pall A Moody J Davidson AVM Davidson DLW The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol 1986; 22: 725–28

Kutt H Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 1984; 25 (suppl 2): 118–31

Dam M Christiansen J Interaction of propoxyphene with carbamazepine. Lancet 1977: 2: 509

Schmidt D Cornaggia C Fabian A Carbamazepine suspension for acute treatment of trigeminal neuralgia: clinical effects in relation to plasma concentration. In: Levy . eds Metabolism of antiepileptic drugs. New York: Raven Press 1984: 35 42

Tomson T Ekbom K Trigeminal neuralgia: time course of pain in relation to carbamazepine dosing. Cephalalgia 1981; 1: 91–7

Faigle JW Feldman KF Baltzer V Anticonvulsant effect of carbamazepine. An attempt to distinguish between the potency of the parent drug and its epoxide metabolite. In: Garner-Thorpe . eds Antiepileptic drug monitoring. Avon: Pitman Press 1977: 104 8

Tomson T Bertilsson L Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia. Arch Neurol 1984; 41: 598–601